Publications by authors named "Mark Watling"

Claim this Profile
O
Overview of preclinical and clinical studies investigating pharmacokinetics and drug-drug interactions of padsevonil.
Hugues Chanteux, Merran MacPherson, Hester Kramer, Christian Otoul, Takuya Okagaki, Mark Watling

Expert Opin Drug Metab Toxicol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Bridging Studies and Modeling Approach for Implementation of a Patient Centric Sampling Technique in Padsevonil Clinical Development.
Hester Kramer, Ceyhun Bicer, Christian Otoul, Chiara Rospo, Merran Macpherson, Mark Watling

AAPS J· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma ATN(I) classification and precision pharmacology in Alzheimer's disease.
Bruno P Imbimbo, Mark Watling, Camillo Imbimbo, Robert Nisticò

Alzheimers Dement· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial failures of anti-tau antibodies in Alzheimer's disease are reminiscent of the amyloid-β story.
Bruno P Imbimbo, Claudia Balducci, Stefania Ippati, Mark Watling

Neural Regen Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?
Madia Lozupone, Bruno Pietro Imbimbo, Claudia Balducci, Filomena Lo Vecchio, Paola Bisceglia, Mark Watling

Alzheimers Dement· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
Bruno P Imbimbo, Stefania Ippati, Mark Watling, Camillo Imbimbo

Pharmacol Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A critical appraisal of tau-targeting therapies for primary and secondary tauopathies.
Bruno P Imbimbo, Stefania Ippati, Mark Watling, Claudia Balducci

Alzheimers Dement· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?
Filomena Lo Vecchio, Paola Bisceglia, Bruno Pietro Imbimbo, Madia Lozupone, Raffaela Rita Latino, Mark Watling

Ther Adv Chronic Dis· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What have we learned from past failures of investigational drugs for Alzheimer's disease?
Bruno P Imbimbo, Mark Watling

Expert Opin Investig Drugs· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerating Alzheimer's disease drug discovery and development: what's the way forward?
Bruno P Imbimbo, Stefania Ippati, Mark Watling, Claudia Balducci

Expert Opin Drug Discov· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease.
Harald Hampel, Filippo Caraci, A Claudio Cuello, Giuseppe Caruso, Robert Nisticò, Mark Watling

Front Immunol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interventional Psychiatry: An Idea Whose Time Has Come?
Peter Giacobbe, Enoch Ng, Daniel M Blumberger, Zafiris J Daskalakis, Jonathan Downar, Mark Watling

Can J Psychiatry· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism.
Francesco Panza, Madia Lozupone, Mark Watling, Bruno P Imbimbo

Expert Opin Pharmacother· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can Anti-β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?
Bruno P Imbimbo, Ugo Lucca, Mark Watling

Neurol Genet· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer's disease or should they be looking elsewhere?
Bruno Pietro Imbimbo, Stefania Ippati, Mark Watling

Expert Opin Drug Discov· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives.
Bruno P Imbimbo, Madia Lozupone, Mark Watling, Francesco Panza

Expert Opin Investig Drugs· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders.
Francesco Panza, Madia Lozupone, Davide Seripa, Antonio Daniele, Mark Watling

Nat Rev Neurol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?
Bruno P Imbimbo, Stefania Ippati, Ferdinando Ceravolo, Mark Watling

Alzheimers Dement (N Y)· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Striatum-Mediated Deficits in Stimulus-Response Learning and Decision-Making in OCD.
Nole M Hiebert, Marc R Lawrence, Hooman Ganjavi, Mark Watling, Adrian M Owen

Front Psychiatry· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigational BACE inhibitors for the treatment of Alzheimer's disease.
Bruno P Imbimbo, Mark Watling

Expert Opin Investig Drugs· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to test antibacterial therapy in Alzheimer's disease.
Francesco Panza, Madia Lozupone, Vincenzo Solfrizzi, Mark Watling, Bruno P Imbimbo

Brain· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Sophie Glatt, Peter C Taylor, Iain B McInnes, Georg Schett, Robert Landewé, Mark I L Watling

Ann Rheum Dis· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?
Francesco Panza, Madia Lozupone, Mark Watling, Bruno Pietro Imbimbo

Expert Rev Neurother· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
Sophie Glatt, Dominique Baeten, Terry Baker, Meryn Griffiths, Lucian Ionescu, Mark I L Watling

Ann Rheum Dis· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.
Eric Helmer, Mark Watling, Emma Jones, Dominique Tytgat, Mark Jones

Eur J Clin Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis